This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Collaboration streamlines patient access to oncology clinical trials
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
Comprehensive clinical development programs being initiated for each investigational candidate
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Subscribe To Our Newsletter & Stay Updated
